{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:26:27Z","timestamp":1790483187218,"version":"4.1.0"},"reference-count":140,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The chronic and progressive nature of diabetes is usually associated with micro- and macrovascular complications where failure of pancreatic \u03b2-cell function and a general condition of hyperglycaemia is created. One possible factor is failure of the patient to comply with and adhere to the prescribed insulin due to the inconvenient administration route. This review summarizes the rationale for oral insulin administration, existing barriers and some counter-strategies trialled.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>Oral insulin mimics the physiology of endogenous insulin secreted by pancreas. Following the intestinal absorption of oral insulin, it reaches the liver at high concentration via the portal vein. Oral insulin on the other hand has the potential to protect pancreatic \u03b2-cells from autoimmune destruction. Structural modification, targeting a particular tissue\/receptor, and the use of innovative pharmaceutical formulations such as nanoparticles represent strategies introduced to improve oral insulin bioavailability. They showed promising results in overcoming the hurdles facing oral insulin delivery, although delivery is far from ideal.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>The use of advanced pharmaceutical technologies and further research in particulate carrier system delivery predominantly nanoparticle utilization would offer useful tools in delivering insulin via the oral route which in turn would potentially improve diabetic patient compliance to insulin and the overall management of diabetes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/jphp.12852","type":"journal-article","created":{"date-parts":[[2017,11,29]],"date-time":"2017-11-29T17:17:50Z","timestamp":1511975870000},"page":"197-213","source":"Crossref","is-referenced-by-count":155,"title":["Oral insulin delivery: existing barriers and current counter-strategies"],"prefix":"10.1093","volume":"70","author":[{"given":"Ahmed","family":"Gedawy","sequence":"first","affiliation":[{"name":"School of Pharmacy and Biomedical Science, Curtin University , Bentley, WA,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Martinez","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Biomedical Science, Curtin University , Bentley, WA,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0049-6969","authenticated-orcid":false,"given":"Hani","family":"Al-Salami","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Biomedical Science, Curtin University , Bentley, WA,","place":["Australia"]},{"name":"Curtin Health Innovation Research Institute , Bentley, WA,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7087-7957","authenticated-orcid":false,"given":"Crispin R","family":"Dass","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Biomedical Science, Curtin University , Bentley, WA,","place":["Australia"]},{"name":"Curtin Health Innovation Research Institute , Bentley, WA,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,2,1]]},"reference":[{"key":"2024103012323535000_jphp12852-cit-0001","first-page":"16","article-title":"Long-awaited dream of oral insulin: where did we reach?","volume":"4","author":"Madhav","year":"2011","journal-title":"Asian J Pharm Clin Res"},{"key":"2024103012323535000_jphp12852-cit-0002","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/0735-6757(93)90018-7","article-title":"Gas gangrene from subcutaneous insulin administration","volume":"11","author":"Chin","year":"1993","journal-title":"Am J Emerg Med"},{"key":"2024103012323535000_jphp12852-cit-0003","doi-asserted-by":"crossref","first-page":"465","DOI":"10.7326\/0003-4819-144-7-200604040-00005","article-title":"Improvements in diabetes processes of care and intermediate outcomes: United States, 1988\u20132002","volume":"144","author":"Saaddine","year":"2006","journal-title":"Ann Intern Med"},{"key":"2024103012323535000_jphp12852-cit-0004","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0140-6736(97)06234-X","article-title":"Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus","volume":"350","author":"Morris","year":"1997","journal-title":"Lancet"},{"key":"2024103012323535000_jphp12852-cit-0005","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1177\/1932296814529988","article-title":"Oral insulin reloaded: a structured approach","volume":"8","author":"Zijlstra","year":"2014","journal-title":"J Diabetes Sci Technol"},{"key":"2024103012323535000_jphp12852-cit-0006","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/diabetes.51.6.1663","article-title":"Direct and indirect effects of insulin on glucose uptake and storage by the liver","volume":"51","author":"Satake","year":"2002","journal-title":"Diabetes"},{"key":"2024103012323535000_jphp12852-cit-0007","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.2147\/DDDT.S79322","article-title":"Insulin administration: present strategies and future directions for a noninvasive (possibly more physiological) delivery","volume":"9","author":"Matteucci","year":"2015","journal-title":"Drug Des Dev Ther"},{"key":"2024103012323535000_jphp12852-cit-0008","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1001\/archinte.161.19.2293","article-title":"Continuous subcutaneous insulin infusion: a comprehensive review of insulin pump therapy","volume":"161","author":"Lenhard","year":"2001","journal-title":"Arch Intern Med"},{"key":"2024103012323535000_jphp12852-cit-0009","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/S0168-8227(11)70027-4","article-title":"Treatment of type 1 diabetes in children and adolescents using modern insulin pumps","volume":"93","author":"Kordonouri","year":"2011","journal-title":"Diabetes Res Clin Pract"},{"key":"2024103012323535000_jphp12852-cit-0010","doi-asserted-by":"crossref","first-page":"141","DOI":"10.4103\/0973-8398.139177","article-title":"Novel noninvasive techniques in management of diabetes","volume":"8","author":"Sameer","year":"2014","journal-title":"Asian J Pharm"},{"key":"2024103012323535000_jphp12852-cit-0011","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003088-199733040-00004","article-title":"Pharmacokinetic considerations of new insulin formulations and routes of administration","volume":"33","author":"Hoffman","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"2024103012323535000_jphp12852-cit-0012","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nrd836","article-title":"New horizons-alternative routes for insulin therapy","volume":"1","author":"Owens","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"2024103012323535000_jphp12852-cit-0013","doi-asserted-by":"crossref","first-page":"6849","DOI":"10.1016\/j.biomaterials.2010.05.042","article-title":"Biodistribution, pharmacodynamics and pharmacokinetics of insulin analogues in a rat model: oral delivery using pH-responsive nanoparticles vs. subcutaneous injection","volume":"31","author":"Sonaje","year":"2010","journal-title":"Biomaterials"},{"key":"2024103012323535000_jphp12852-cit-0014","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1177\/193229680900300322","article-title":"Oral insulin: the rationale for this approach and current developments","volume":"3","author":"Arbit","year":"2009","journal-title":"J Diabetes Sci Technol"},{"key":"2024103012323535000_jphp12852-cit-0015","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1172\/JCI114142","article-title":"Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance","volume":"84","author":"Groop","year":"1989","journal-title":"J Clin Investig"},{"key":"2024103012323535000_jphp12852-cit-0016","first-page":"E630","article-title":"Dose-response characteristics for effects of insulin on production and utilization of glucose in man","volume":"240","author":"Rizza","year":"1981","journal-title":"Am J Physiol"},{"key":"2024103012323535000_jphp12852-cit-0017","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.2337\/diabetes.51.2007.S103","article-title":"Physiological consequences of phasic insulin release in the normal animal","volume":"51","author":"Cherrington","year":"2002","journal-title":"Diabetes"},{"key":"2024103012323535000_jphp12852-cit-0018","first-page":"433","article-title":"Oral administration of insulin to female nonobese diabetic mice inhibited diabetes and induced Fas ligand expression on islets of Langerhans","volume":"113","author":"Wang","year":"2000","journal-title":"Chin Med J"},{"key":"2024103012323535000_jphp12852-cit-0019","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1210\/10.1210\/er.2006-0038","article-title":"\u0392-cell failure in diabetes and preservation by clinical treatment","volume":"28","author":"Wajchenberg","year":"2007","journal-title":"Endocr Rev"},{"key":"2024103012323535000_jphp12852-cit-0020","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"2024103012323535000_jphp12852-cit-0021","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.2337\/diabetes.48.9.1720","article-title":"Insulin B-chain reactive CD 4+ regulatory T-cells induced by oral insulin treatment protect from type 1 diabetes by blocking the cytokine secretion and pancreatic infiltration of diabetogenic effector T-cells","volume":"48","author":"Bergerot","year":"1999","journal-title":"Diabetes"},{"key":"2024103012323535000_jphp12852-cit-0022","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0167-7799(97)01170-0","article-title":"Innovative strategies for the oral delivery of drugs and peptides","volume":"16","author":"Fasano","year":"1998","journal-title":"Trends Biotechnol"},{"key":"2024103012323535000_jphp12852-cit-0023","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0168-3659(96)01352-1","article-title":"Structural requirements for intestinal absorption of peptide drugs","volume":"41","author":"Pauletti","year":"1996","journal-title":"J Control Release"},{"key":"2024103012323535000_jphp12852-cit-0024","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1758-5996-2-66","article-title":"Oral insulin","volume":"2","author":"Kalra","year":"2010","journal-title":"Diabetol Metab Syndr"},{"key":"2024103012323535000_jphp12852-cit-0025","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1146\/annurev.me.41.020190.002141","article-title":"Intestinal barriers to bacteria and their toxins","volume":"41","author":"Walker","year":"1990","journal-title":"Annu Rev Med"},{"key":"2024103012323535000_jphp12852-cit-0026","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0016-5085(70)80092-0","article-title":"Surface structure of intestinal epithelium","volume":"58","author":"Balcerzak","year":"1970","journal-title":"Gastroenterology"},{"key":"2024103012323535000_jphp12852-cit-0027","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/aja.1001410407","article-title":"Origin, differentiation and renewal of the four main epithelial cell types in the mouse small intestine. V. Unitarian theory of the origin of the four epithelial cell types","volume":"141","author":"Cheng","year":"1974","journal-title":"Am J Anat"},{"key":"2024103012323535000_jphp12852-cit-0028","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/gut.6.3.225","article-title":"Number, size, and distribution of Peyer's patches in the human small intestine","volume":"6","author":"Cornes","year":"1965","journal-title":"Gut"},{"key":"2024103012323535000_jphp12852-cit-0029","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nri1439","article-title":"Nalt- versus peyer's-patch-mediated mucosal immunity","volume":"4","author":"Hiroshi","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"2024103012323535000_jphp12852-cit-0030","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1172\/JCI113987","article-title":"Loosening tight junctions. Lessons from the intestine","volume":"83","author":"Madara","year":"1989","journal-title":"J Clin Invest"},{"key":"2024103012323535000_jphp12852-cit-0031","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.addr.2006.01.003","article-title":"Tight junction modulation and its relationship to drug delivery","volume":"58","author":"Salama","year":"2006","journal-title":"Adv Drug Deliv Rev"},{"key":"2024103012323535000_jphp12852-cit-0032","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1023\/A:1011948703571","article-title":"The influence of intestinal mucus components on the diffusion of drugs","volume":"15","author":"Larhed","year":"1998","journal-title":"Pharm Res"},{"key":"2024103012323535000_jphp12852-cit-0033","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0169-409X(93)90010-2","article-title":"The effect of gastro-intestinal mucus on drug absorption","volume":"11","author":"Macadam","year":"1993","journal-title":"Adv Drug Deliv Rev"},{"key":"2024103012323535000_jphp12852-cit-0034","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.addr.2008.09.008","article-title":"Barrier properties of mucus","volume":"61","author":"Cone","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"key":"2024103012323535000_jphp12852-cit-0035","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0928-0987(97)10019-7","article-title":"Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs\u2019 lipophilicity and molecular weight","volume":"6","author":"Camenisch","year":"1998","journal-title":"Eur J Pharm Sci"},{"key":"2024103012323535000_jphp12852-cit-0036","doi-asserted-by":"crossref","first-page":"S449","DOI":"10.1155\/2010\/147824","article-title":"A validated RP-HPLC method for the determination of recombinant human insulin in bulk and pharmaceutical dosage form","volume":"7","author":"Moussa","year":"2010","journal-title":"J Chem"},{"key":"2024103012323535000_jphp12852-cit-0037","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1136\/gut.29.8.1035","article-title":"Measurement of gastrointestinal pH profiles in normal ambulant human subjects","volume":"29","author":"Evans","year":"1988","journal-title":"Gut"},{"key":"2024103012323535000_jphp12852-cit-0038","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1021\/cr000700m","article-title":"Peroral route: an opportunity for protein and peptide drug delivery","volume":"101","author":"Sood","year":"2001","journal-title":"Chem Rev"},{"key":"2024103012323535000_jphp12852-cit-0039","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0168-3659(96)01586-6","article-title":"The challenge of proteolytic enzymes in intestinal peptide delivery","volume":"46","author":"Langguth","year":"1997","journal-title":"J Control Release"},{"key":"2024103012323535000_jphp12852-cit-0040","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1023\/A:1015893832222","article-title":"Degradation of insulin by trypsin and alpha-chymotrypsin","volume":"8","author":"Schilling","year":"1991","journal-title":"Pharm Res"},{"key":"2024103012323535000_jphp12852-cit-0041","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1023\/A:1016024322209","article-title":"Evidence for the existence of insulin-degrading enzyme on the brush-border membranes of rat enterocytes","volume":"13","author":"Chang","year":"1996","journal-title":"Pharm Res"},{"key":"2024103012323535000_jphp12852-cit-0042","doi-asserted-by":"crossref","first-page":"188","DOI":"10.2337\/diacare.7.2.188","article-title":"Insulin pharmacokinetics","volume":"7","author":"Binder","year":"1984","journal-title":"Diabetes Care"},{"key":"2024103012323535000_jphp12852-cit-0043","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/nature13297","article-title":"Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones","volume":"511","author":"Juan Pablo","year":"2014","journal-title":"Nature"},{"key":"2024103012323535000_jphp12852-cit-0044","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0169-409X(98)00075-1","article-title":"Oral insulin delivery","volume":"35","author":"Carino","year":"1999","journal-title":"Adv Drug Deliv Rev"},{"key":"2024103012323535000_jphp12852-cit-0045","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrd1067","article-title":"Challenges for the oral delivery of macromolecules","volume":"2","author":"Michael","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"2024103012323535000_jphp12852-cit-0046","first-page":"76","article-title":"Current status of the oral delivery of insulin","volume":"25","author":"Agarwal","year":"2001","journal-title":"Pharm Technol"},{"key":"2024103012323535000_jphp12852-cit-0047","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v20.i23.30","article-title":"Emerging trends in oral delivery of peptide and protein drugs","volume":"20","author":"Mahato","year":"2003","journal-title":"Crit Rev Ther Drug Carr Syst"},{"key":"2024103012323535000_jphp12852-cit-0048","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0169-409X(02)00022-4","article-title":"Chemistry for peptide and protein pegylation","volume":"54","author":"Roberts","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"key":"2024103012323535000_jphp12852-cit-0049","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0169-409X(02)00025-X","article-title":"Effects of peg conjugation on insulin properties","volume":"54","author":"Hinds","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"key":"2024103012323535000_jphp12852-cit-0050","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0169-409X(02)00180-1","article-title":"Effective drug delivery by pegylated drug conjugates","volume":"55","author":"Greenwald","year":"2003","journal-title":"Adv Drug Deliv Rev"},{"key":"2024103012323535000_jphp12852-cit-0051","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1089\/152091502760306544","article-title":"Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in type 1 diabetes mellitus: the glucose stabilization effects of HIM2","volume":"4","author":"Clement","year":"2002","journal-title":"Diabetes Technol Ther"},{"key":"2024103012323535000_jphp12852-cit-0052","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1046\/j.1464-5491.2003.01076.x","article-title":"Alternative routes of insulin delivery","volume":"20","author":"Owens","year":"2003","journal-title":"Diabet Med"},{"key":"2024103012323535000_jphp12852-cit-0053","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.drudis.2006.08.005","article-title":"Is the oral route possible for peptide and protein drug delivery?","volume":"11","author":"Morishita","year":"2006","journal-title":"Drug Discov Today"},{"key":"2024103012323535000_jphp12852-cit-0054","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.2337\/diacare.27.12.2868","article-title":"Dose-response effect of a single administration of oral hexyl-insulin to monoconjugate 2 in healthy nondiabetic subjects","volume":"27","author":"Wajcberg","year":"2004","journal-title":"Diabetes Care"},{"key":"2024103012323535000_jphp12852-cit-0055","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1177\/193229680900300323","article-title":"Oral insulin and buccal insulin: a critical reappraisal","volume":"3","author":"Heinemann","year":"2009","journal-title":"J Diabetes Sci Technol"},{"key":"2024103012323535000_jphp12852-cit-0056","doi-asserted-by":"crossref","first-page":"313","DOI":"10.4155\/ppa.14.15","article-title":"Formulation strategies to improve oral peptide delivery","volume":"3","author":"Maher","year":"2014","journal-title":"Pharm Pat Anal"},{"key":"2024103012323535000_jphp12852-cit-0057","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1464-5491.2004.01160.x","article-title":"A novel per-oral insulin formulation: proof of concept study in non-diabetic subjects","volume":"21","author":"Kidron","year":"2004","journal-title":"Diabet Med"},{"key":"2024103012323535000_jphp12852-cit-0058","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jconrel.2007.05.019","article-title":"Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles","volume":"122","author":"Chalasani","year":"2007","journal-title":"J Control Release"},{"key":"2024103012323535000_jphp12852-cit-0059","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.addr.2011.12.014","article-title":"Oral biodrug delivery using cell-penetrating peptide","volume":"64","author":"Khafagy","year":"2012","journal-title":"Adv Drug Deliv Rev"},{"key":"2024103012323535000_jphp12852-cit-0060","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ejpb.2004.02.018","article-title":"Chances and pitfalls of cell penetrating peptides for cellular drug delivery","volume":"58","author":"Tr\u00e9hin","year":"2004","journal-title":"Eur J Pharm Biopharm"},{"key":"2024103012323535000_jphp12852-cit-0061","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s10867-008-9074-3","article-title":"Cell penetrating peptides: how do they do it?","volume":"33","author":"Herce","year":"2007","journal-title":"J Biol Phys"},{"key":"2024103012323535000_jphp12852-cit-0062","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.bbrc.2005.07.142","article-title":"Insulin-cell penetrating peptide hybrids with improved intestinal absorption efficiency","volume":"335","author":"Liang","year":"2005","journal-title":"Biochem Biophys Res Comm"},{"key":"2024103012323535000_jphp12852-cit-0063","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0169-409X(01)00197-1","article-title":"Chitosan for mucosal vaccination","volume":"52","author":"Van Der Lubben","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"key":"2024103012323535000_jphp12852-cit-0064","first-page":"144","article-title":"Uptake and translocation of fluorescent latex-particles by rabbit Peyer's patch follicle epithelium \u2013 a quantitative model for M cell uptake","volume":"76","author":"Pappo","year":"1989","journal-title":"Clin Exp Immunol"},{"key":"2024103012323535000_jphp12852-cit-0065","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0378-5173(02)00486-6","article-title":"Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo","volume":"249","author":"Pan","year":"2002","journal-title":"Int J Pharm"},{"key":"2024103012323535000_jphp12852-cit-0066","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1463-1326.2009.01150.x","article-title":"Oral insulin \u2013 a review of current status","volume":"12","author":"Iyer","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"2024103012323535000_jphp12852-cit-0067","first-page":"1496","article-title":"Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats","volume":"11","author":"Yamamoto","year":"1994","journal-title":"AAPS PharmSciTech"},{"key":"2024103012323535000_jphp12852-cit-0068","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1211\/146080800128735935","article-title":"Oral delivery of proteins: effect of chicken and duck ovomucoid on the stability of insulin in the presence of \u03b1-chymotrypsin and trypsin","volume":"6","author":"Agarwal","year":"2000","journal-title":"Pharm Pharmacol Commun"},{"key":"2024103012323535000_jphp12852-cit-0069","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/(SICI)1520-6017(200004)89:4<429::AID-JPS1>3.0.CO;2-J","article-title":"Intestinal permeation enhancers","volume":"89","author":"Aungst","year":"2000","journal-title":"J Pharm Sci"},{"key":"2024103012323535000_jphp12852-cit-0070","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.4155\/tde.11.114","article-title":"Oral peptide delivery: prioritizing the leading technologies","volume":"2","author":"Brayden","year":"2011","journal-title":"Ther Deliv"},{"key":"2024103012323535000_jphp12852-cit-0071","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1172\/JCI119271","article-title":"Modulation of intestinal tight junctions by zonula occludens toxin permits enteral administration of insulin and other macromolecules in an animal model","volume":"99","author":"Fasano","year":"1997","journal-title":"J Clin Investig"},{"key":"2024103012323535000_jphp12852-cit-0072","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0378-5173(86)90069-4","article-title":"Targeted enteral delivery of insulin to rats","volume":"30","author":"Touitou","year":"1986","journal-title":"Int J Pharm"},{"key":"2024103012323535000_jphp12852-cit-0073","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1208\/pt030433","article-title":"In vitro evaluation of dissolution behavior for a colon-specific drug delivery system (CODES\u2122) in multi-pH media using United States pharmacopeia apparatus II and III","volume":"3","author":"Li","year":"2002","journal-title":"AAPS PharmSciTech"},{"key":"2024103012323535000_jphp12852-cit-0074","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ijpharm.2005.09.028","article-title":"Effects of absorption promoters on insulin absorption through colon-targeted delivery","volume":"307","author":"Katsuma","year":"2006","journal-title":"Int J Pharm"},{"key":"2024103012323535000_jphp12852-cit-0075","volume-title":"Capsulin\u2122","author":"Diabetology Ltd","year":"2017"},{"key":"2024103012323535000_jphp12852-cit-0076","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1517\/17425247.2012.737779","article-title":"Novel non-invasive methods of insulin delivery","volume":"9","author":"Soares","year":"2012","journal-title":"Expert Opin Drug Deliv"},{"key":"2024103012323535000_jphp12852-cit-0077","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1463-1326.2009.01146.x","article-title":"The glucose lowering effect of an oral insulin (capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes","volume":"12","author":"Luzio","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"2024103012323535000_jphp12852-cit-0078","volume-title":"Methods and compositions for oral administration of proteins","author":"Miriam","year":"2011"},{"key":"2024103012323535000_jphp12852-cit-0079","volume-title":"Oral insulin delivery pipeline","author":"Oramed Pharmaceuticals","year":"2017"},{"key":"2024103012323535000_jphp12852-cit-0080","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0168-3659(01)00232-2","article-title":"Development and characterization of a novel peroral peptide drug delivery system","volume":"71","author":"Dorkoosh","year":"2001","journal-title":"J Control Release"},{"key":"2024103012323535000_jphp12852-cit-0081","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ijpharm.2007.08.051","article-title":"Beneficial properties for insulin absorption using superporous hydrogel containing interpenetrating polymer network as oral delivery vehicles","volume":"350","author":"Yin","year":"2008","journal-title":"Int J Pharm"},{"key":"2024103012323535000_jphp12852-cit-0082","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1016\/j.biomaterials.2010.01.045","article-title":"Polymer integrity related absorption mechanism of superporous hydrogel containing interpenetrating polymer networks for oral delivery of insulin","volume":"31","author":"Yin","year":"2010","journal-title":"Biomaterials"},{"key":"2024103012323535000_jphp12852-cit-0083","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.addr.2005.07.001","article-title":"The basics and underlying mechanisms of mucoadhesion","volume":"57","author":"Smart","year":"2005","journal-title":"Adv Drug Deliv Rev"},{"key":"2024103012323535000_jphp12852-cit-0084","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0168-3659(99)00228-X","article-title":"Lectin-mediated drug delivery: the second generation of bioadhesives","volume":"65","author":"Lehr","year":"2000","journal-title":"J Control Release"},{"key":"2024103012323535000_jphp12852-cit-0085","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.addr.2005.07.002","article-title":"Thiomers: a new generation of mucoadhesive polymers","volume":"57","author":"Bernkop-Schn\u00fcrch","year":"2005","journal-title":"Adv Drug Deliv Rev"},{"key":"2024103012323535000_jphp12852-cit-0086","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jconrel.2003.12.017","article-title":"Oral insulin delivery: the potential of thiolated chitosan-insulin tablets on non-diabetic rats","volume":"95","author":"Krauland","year":"2004","journal-title":"J Control Release"},{"key":"2024103012323535000_jphp12852-cit-0087","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ijpharm.2016.01.022","article-title":"Insulin loaded mucus permeating nanoparticles: addressing the surface characteristics as feature to improve mucus permeation","volume":"500","author":"Pereira De Sousa","year":"2016","journal-title":"Int J Pharm"},{"key":"2024103012323535000_jphp12852-cit-0088","article-title":"Pegylation for enhancing nanoparticle diffusion in mucus","author":"Huckaby","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"issue":"Suppl. C","key":"2024103012323535000_jphp12852-cit-0089","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jconrel.2015.12.008","article-title":"Efficient mucus permeation and tight junction opening by dissociable \u201cmucus-inert\u201d agent coated trimethyl chitosan nanoparticles for oral insulin delivery","volume":"222","author":"Liu","year":"2016","journal-title":"J Control Release"},{"key":"2024103012323535000_jphp12852-cit-0090","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3109\/02652048.2012.742159","article-title":"Microencapsulation techniques to develop formulations of insulin for oral delivery: a review","volume":"30","author":"Crdenas-Bailn","year":"2013","journal-title":"J Microencapsul"},{"key":"2024103012323535000_jphp12852-cit-0091","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2165\/00063030-200519030-00003","article-title":"Oral delivery of peptide drugs","volume":"19","author":"Hamman","year":"2005","journal-title":"BioDrugs"},{"key":"2024103012323535000_jphp12852-cit-0092","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/BF00318501","article-title":"Uptake and transport of copolymer biodegradable microspheres by rabbit Peyer's patch M cells","volume":"279","author":"Ermak","year":"1995","journal-title":"Cell Tissue Res"},{"key":"2024103012323535000_jphp12852-cit-0093","first-page":"1051","article-title":"Relationship between drug effects and particle size of insulin-loaded bioadhesive microspheres","volume":"23","author":"Pan","year":"2002","journal-title":"Acta Pharmacol Sin"},{"key":"2024103012323535000_jphp12852-cit-0094","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1211\/jpp.59.10.0003","article-title":"Development and in-vivo evaluation of insulin-loaded chitosan phthalate microspheres for oral delivery","volume":"59","author":"Ubaidulla","year":"2007","journal-title":"J Pharm Pharmacol"},{"key":"2024103012323535000_jphp12852-cit-0095","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jconrel.2005.05.022","article-title":"An enteric-coated dry emulsion formulation for oral insulin delivery","volume":"107","author":"Toorisaka","year":"2005","journal-title":"J Control Release"},{"key":"2024103012323535000_jphp12852-cit-0096","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejpb.2010.07.002","article-title":"Microemulsions for oral delivery of insulin: design, development and evaluation in streptozotocin induced diabetic rats","volume":"76","author":"Sharma","year":"2010","journal-title":"Eur J Pharm Biopharm"},{"key":"2024103012323535000_jphp12852-cit-0097","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1517\/17425247.2012.717068","article-title":"Oral delivery of peptides and proteins using lipid-based drug delivery systems","volume":"9","author":"Li","year":"2012","journal-title":"Expert Opin Drug Deliv"},{"key":"2024103012323535000_jphp12852-cit-0098","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/0014-5793(76)80016-6","article-title":"Oral administration of insulin by encapsulation within liposomes","volume":"62","author":"Patel","year":"1976","journal-title":"FEBS Lett"},{"key":"2024103012323535000_jphp12852-cit-0099","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1177\/193229680900300627","article-title":"Hepatic-directed vesicle insulin: a review of formulation development and preclinical evaluation","volume":"3","author":"Geho","year":"2009","journal-title":"J Diabetes Sci Technol"},{"key":"2024103012323535000_jphp12852-cit-0100","volume-title":"Insulin therapies for the treatment of diabetes, diabetes related ailments, and\/or diseases or conditions other than diabetes or diabetes related ailments","author":"Blair Geho","year":"2012"},{"key":"2024103012323535000_jphp12852-cit-0101","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.addr.2007.04.007","article-title":"Solid lipid nanoparticles as a drug delivery system for peptides and proteins","volume":"59","author":"Almeida","year":"2007","journal-title":"Adv Drug Deliv Rev"},{"key":"2024103012323535000_jphp12852-cit-0102","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0939-6411(00)00087-4","article-title":"Solid lipid nanoparticles (SLN) for controlled drug delivery \u2013 a review of the state of the art","volume":"50","author":"M\u00fcller","year":"2000","journal-title":"Eur J Pharm Biopharm"},{"key":"2024103012323535000_jphp12852-cit-0103","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0927-7765(02)00053-X","article-title":"Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules","volume":"27","author":"Garcia-Fuentes","year":"2003","journal-title":"Colloid Surf B Biointerfaces"},{"key":"2024103012323535000_jphp12852-cit-0104","first-page":"1","article-title":"From nanoemulsions to self-nanoemulsions, with recent advances in self-nanoemulsifying drug delivery systems (SNEDDS)","volume":"00","author":"Rehman","year":"2016","journal-title":"Expert Opin Drug Deliv"},{"key":"2024103012323535000_jphp12852-cit-0105","article-title":"Nanoemulsions \u2013 advances in formulation, characterization and applications in drug delivery, application of nanotechnology in drug delivery","author":"Chime","year":"2014","journal-title":"InTech"},{"key":"2024103012323535000_jphp12852-cit-0106","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ijpharm.2008.05.018","article-title":"Self-nanoemulsifying drug delivery systems (SNEDDS) for oral delivery of protein drugs: I. Formulation development","volume":"362","author":"Rao","year":"2008","journal-title":"Int J Pharm"},{"key":"2024103012323535000_jphp12852-cit-0107","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ijbiomac.2013.08.002","article-title":"Combining two technologies: multifunctional polymers and self-nanoemulsifying drug delivery system (SNEDDS) for oral insulin administration","volume":"61","author":"Sakloetsakun","year":"2013","journal-title":"Int J Biol Macromol"},{"key":"2024103012323535000_jphp12852-cit-0108","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1166\/jbn.2012.1371","article-title":"The in vitro and in vivo study on self-nanoemulsifying drug delivery system (SNEDDS) based on insulin-phospholipid complex","volume":"8","author":"Zhang","year":"2012","journal-title":"J Biomed Nanotechnol"},{"key":"2024103012323535000_jphp12852-cit-0109","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ejpb.2015.04.013","article-title":"Effective incorporation of insulin in mucus permeating self-nanoemulsifying drug delivery systems","volume":"97","author":"Karamanidou","year":"2015","journal-title":"Eur J Pharm Biopharm"},{"key":"2024103012323535000_jphp12852-cit-0110","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jconrel.2004.07.030","article-title":"Transmucosal macromolecular drug delivery","volume":"101","author":"Prego","year":"2005","journal-title":"J Control Release"},{"key":"2024103012323535000_jphp12852-cit-0111","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1177\/193229681300700228","article-title":"Oral insulin delivery: how far are we?","volume":"7","author":"Fonte","year":"2013","journal-title":"J Diabetes Sci Technol"},{"key":"2024103012323535000_jphp12852-cit-0112","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.drudis.2012.03.019","article-title":"An overview of natural polymers for oral insulin delivery","volume":"17","author":"Sonia","year":"2012","journal-title":"Drug Discov Today"},{"key":"2024103012323535000_jphp12852-cit-0113","doi-asserted-by":"crossref","first-page":"9826","DOI":"10.1016\/j.biomaterials.2011.08.087","article-title":"A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery","volume":"32","author":"Chen","year":"2011","journal-title":"Biomaterials"},{"key":"2024103012323535000_jphp12852-cit-0114","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1007\/s00018-009-0053-z","article-title":"Nanocarriers\u2019 entry into the cell: relevance to drug delivery","volume":"66","author":"Hillaireau","year":"2009","journal-title":"Cell Mol Life Sci"},{"key":"2024103012323535000_jphp12852-cit-0115","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ddtec.2005.05.019","article-title":"Nanoparticle uptake by the oral route: fulfilling its potential?","volume":"2","author":"Florence","year":"2005","journal-title":"Drug Discov Today Technol"},{"key":"2024103012323535000_jphp12852-cit-0116","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1021\/la051982u","article-title":"Gold nanoparticles as carriers for efficient transmucosal insulin delivery","volume":"22","author":"Joshi","year":"2006","journal-title":"Langmuir"},{"key":"2024103012323535000_jphp12852-cit-0117","doi-asserted-by":"crossref","first-page":"125","DOI":"10.4155\/tde.10.109","article-title":"Nanoparticles and toxicity in therapeutic delivery: the ongoing debate","volume":"2","author":"Sharif","year":"2011","journal-title":"Ther Deliv"},{"key":"2024103012323535000_jphp12852-cit-0118","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1126\/science.1114397","article-title":"Toxic potential of materials at the nanolevel","volume":"311","author":"Nel","year":"2006","journal-title":"Science"},{"key":"2024103012323535000_jphp12852-cit-0119","first-page":"87","article-title":"The effect of nanoparticle uptake on cellular behavior: disrupting or enabling functions?","volume":"5","author":"Panariti","year":"2012","journal-title":"Nanotechnol Sci Appl"},{"key":"2024103012323535000_jphp12852-cit-0120","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/978-94-017-8739-0_8","article-title":"Nanomaterials: impact on cells and cell organelles","volume":"811","author":"Krpeti\u0107","year":"2014","journal-title":"Adv Exp Med Biol"},{"key":"2024103012323535000_jphp12852-cit-0121","doi-asserted-by":"crossref","first-page":"MR17","DOI":"10.1116\/1.2815690","article-title":"Nanomaterials and nanoparticles: sources and toxicity","volume":"2","author":"Buzea","year":"2007","journal-title":"Biointerphases"},{"key":"2024103012323535000_jphp12852-cit-0122","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0169-409X(02)00228-4","article-title":"Biodegradable nanoparticles for drug and gene delivery to cells and tissue","volume":"55","author":"Panyam","year":"2003","journal-title":"Adv Drug Deliv Rev"},{"key":"2024103012323535000_jphp12852-cit-0123","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/00222930701314932","article-title":"Cellular responses to nanoparticles: target structures and mechanisms","volume":"1","author":"Unfried","year":"2007","journal-title":"Nanotoxicology"},{"key":"2024103012323535000_jphp12852-cit-0124","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/btm2.10015","article-title":"Intestinal mucoadhesive devices for oral delivery of insulin","volume":"1","author":"Banerjee","year":"2016","journal-title":"Bioeng Transl Med"},{"key":"2024103012323535000_jphp12852-cit-0125","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1080\/1061186X.2017.1300664","article-title":"Intestinal micropatches for oral insulin delivery","volume":"25","author":"Banerjee","year":"2017","journal-title":"J Drug Target"},{"key":"2024103012323535000_jphp12852-cit-0126","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.ijpharm.2015.10.078","article-title":"Goblet cell targeting nanoparticle containing drug-loaded micelle cores for oral delivery of insulin","volume":"496","author":"Zhang","year":"2015","journal-title":"Int J Pharm"},{"key":"2024103012323535000_jphp12852-cit-0127","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.xphs.2016.02.018","article-title":"Methocel-lipid hybrid nanocarrier for efficient oral insulin delivery","volume":"105","author":"Boushra","year":"2016","journal-title":"J Pharm Sci"},{"issue":"Suppl. C","key":"2024103012323535000_jphp12852-cit-0128","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.reactfunctpolym.2017.08.014","article-title":"Optimization of pH-responsive carboxymethylated iota-carrageenan\/chitosan nanoparticles for oral insulin delivery using response surface methodology","volume":"119","author":"Sahoo","year":"2017","journal-title":"React Funct Polym"},{"key":"2024103012323535000_jphp12852-cit-0129","doi-asserted-by":"crossref","first-page":"8866","DOI":"10.1021\/acs.jafc.7b03465","article-title":"Binary and tertiary complex based on short-chain glucan and proanthocyanidins for oral insulin delivery","volume":"65","author":"Ji","year":"2017","journal-title":"J Agric Food Chem"},{"key":"2024103012323535000_jphp12852-cit-0130","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.nano.2017.05.002","article-title":"Selenium nanoparticles as versatile carriers for oral delivery of insulin: insight into the synergic antidiabetic effect and mechanism","volume":"13","author":"Deng","year":"2017","journal-title":"Nanomed Nanotechnol Biol Med"},{"issue":"Suppl. C","key":"2024103012323535000_jphp12852-cit-0131","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.eurpolymj.2017.05.015","article-title":"Preparation of polyurethane\u2013alginate\/chitosan core shell nanoparticles for the purpose of oral insulin delivery","volume":"92","author":"Bhattacharyya","year":"2017","journal-title":"Eur Polymer J"},{"key":"2024103012323535000_jphp12852-cit-0132","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3390\/ijms18010054","article-title":"Multifunctional composite microcapsules for oral delivery of insulin","volume":"18","author":"Sun","year":"2017","journal-title":"Int J Mol Sci"},{"key":"2024103012323535000_jphp12852-cit-0133","first-page":"19","article-title":"Insulin and insulin resistance","volume":"26","author":"Wilcox","year":"2005","journal-title":"Clin Biochem Rev"},{"key":"2024103012323535000_jphp12852-cit-0134","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/13813455.2012.754474","article-title":"The metabolic and mitogenic properties of basal insulin analogues","volume":"119","author":"Tennagels","year":"2013","journal-title":"Arch Physiol Biochem"},{"key":"2024103012323535000_jphp12852-cit-0135","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1530\/EC-13-0086","article-title":"Insulin receptor compensates for IGF1R inhibition and directly induces mitogenic activity in prostate cancer cells","volume":"3","author":"Weinstein","year":"2014","journal-title":"Endocr Connect"},{"key":"2024103012323535000_jphp12852-cit-0136","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ecl.2012.04.018","article-title":"Insulin-like growth factors in the gastrointestinal tract and liver","volume":"41","author":"Kuemmerle","year":"2012","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2024103012323535000_jphp12852-cit-0137","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/dmrr.912","article-title":"Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells","volume":"25","author":"Weinstein","year":"2009","journal-title":"Diabetes Metab Res Rev"},{"key":"2024103012323535000_jphp12852-cit-0138","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/jnci\/92.18.1472","article-title":"Role of the insulin-like growth factor family in cancer development and progression","volume":"92","author":"Yu","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"2024103012323535000_jphp12852-cit-0139","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.ygyno.2012.03.012","article-title":"Mitogenic and anti-apoptotic effects of insulin in endometrial cancer are phosphatidylinositol 3-kinase\/Akt dependent","volume":"125","author":"Wang","year":"2012","journal-title":"Gynecol Oncol"},{"key":"2024103012323535000_jphp12852-cit-0140","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00125-009-1558-6","article-title":"Mitogenic action of insulin: friend, foe or \u2018frenemy\u2019?","volume":"53","author":"Draznin","year":"2010","journal-title":"Diabetologia"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjphp.12852","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/70\/2\/197\/60224558\/jphp12852.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/70\/2\/197\/60224558\/jphp12852.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T17:46:29Z","timestamp":1730310389000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/70\/2\/197\/6121783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,1]]},"references-count":140,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,2,1]]},"published-print":{"date-parts":[[2018,2,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jphp.12852","relation":{},"ISSN":["2042-7158","0022-3573"],"issn-type":[{"value":"2042-7158","type":"electronic"},{"value":"0022-3573","type":"print"}],"subject":[],"published-other":{"date-parts":[[2018,2]]},"published":{"date-parts":[[2018,2,1]]}}}